The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Aperture Bio, Inc., a woman-owned small business located in Boston, Massachusetts, a $404,994 Project Grant (R43CA298597) on March 1, 2025. The goal of this 1-year project is to determine the feasibility of using Aperture Bio's platform for preclinical applications in drug development, cell therapy manufacturing, regenerative medicine, cell developmental biology, and oncology research. The project will evaluate Aperture Bio's conjugation and quenching technologies, which can stain and quantify cellular perturbations in live cells across multiple cellular compartments. Successful completion of this project will assess if Aperture Bio's platform is suitable for the rigor required to improve current precision medicine development and delivery approaches.
Generated 3/18/25, 3:10 AM